Adma Biologics (ADMA) Short term Debt (2025 - 2026)

Adma Biologics' (ADMA) quarterly Short term Debt came in at $2.8 million in Q4 2025, up 20.01% on a QoQ basis from $2.3 million in Q3 2025.

Adma Biologics (ADMA) Short term Debt (2025 - 2026) Analysis & Trends

Adma Biologics (ADMA) has 1 years of Short term Debt data on file, last reported at $2.8 million in Q4 2025.

Quarterly Short term Debt changed N/A year-over-year to $2.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.8 million (changed N/A YoY) and the FY2025 annual result came in at $2.8 million, changed N/A from the prior year.
Short term Debt improved to $2.8 million in Q4 2025, from $2.3 million in the prior quarter.
In the past five years, Short term Debt ranged from a high of $2.8 million in Q4 2025 to a low of $2.3 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Adma Biologics	2.13 Bn	2.00 Bn	86.28 Mn

Download Data